Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Savene dexrazoxane: Phase II/III data

July 4, 2005 7:00 AM UTC

Data from an open-label, Danish Phase II/III trial in 18 patients showed a 100% success rate in tissue damage prevention when used within 6 hours following extravasation. Savene has Orphan Drug design...